Zyversa Therapeutics, Inc. (ZVSA) — 10-Q Filings
All 10-Q filings from Zyversa Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
ZyVersa's Q3 Loss Soars on $18.6M R&D Impairment, Cash Dwindles
— Nov 19, 2025 Risk: high
ZyVersa Therapeutics, Inc. reported a significant net loss of $19,805,559 for the three months ended September 30, 2025, a substantial increase from the $2,401, -
ZyVersa's Cash Dries Up Amid Nasdaq Delisting, Going Concern Doubts
— Aug 13, 2025 Risk: high
ZyVersa Therapeutics, Inc. (ZVSA) reported a net loss of $4.47 million for the six months ended June 30, 2025, a 20.08% improvement from the $5.59 million net l -
ZyVersa Therapeutics Files Q1 2025 10-Q
— May 12, 2025 Risk: medium
ZyVersa Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Larkspur Health Acquisition Corp., reported its financial -
ZyVersa Therapeutics Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
ZyVersa Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Larkspur Health Acquisition Corp., is in the pharmaceu - 10-Q Filing — Aug 9, 2024
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX